The identification of irreversible rituximab-resistant lymphoma caused by CD20 gene mutations

Y Mishima1,2, Y Terui1, K Takeuchi1, Y Matsumoto-Mishima1, S Matsusaka1, R Utsubo-Kuniyoshi1,2 and K Hatake1

1Department of Clinical Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan; 2Olympas Bio-Imaging Lab, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo, Japan and 3Division of Pathology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan

C-terminal mutations of CD20 constitute part of the mechanisms that resist rituximab therapy. Most CD20 having a C-terminal mutation was not recognized by L26 antibody. As the exact epitope of L26 has not been determined, expression and localization of mutated CD20 have not been completely elucidated. In this study, we revealed that the binding site of L26 monoclonal antibody is located in the C-terminal cytoplasmic region of CD20 molecule, which was often lost in mutated CD20 molecules. This indicates that it is difficult to distinguish the mutation of CD20 from under expression of the CD20 protein. To detect comprehensive CD20 molecules including the resistant mutants, we developed a novel monoclonal antibody that recognizes the N-terminal cytoplasm region of CD20 molecule. We screened L26-negative cases with our antibody and found several mutations. A rituximab-binding analysis using the cryopreserved specimen that mutation was identified in CD20 molecules indicated that the C-terminal region of CD20 undertakes a critical role in presentation of the large loop in which the rituximab-binding site locates. Thus, combination of antibodies of two kinds of epitope permits the identification of C-terminal CD20 mutations associated with irreversible resistance to rituximab and may help the decision of the treatment strategy.

Blood Cancer Journal (2011) 1, e15; doi:10.1038/bcj.2011.11; published online 8 April 2011

Keywords: B-cell lymphomas; mutations; antibody therapy; CD20; rituximab

Introduction

Previously, we reported that gene mutations of CD20 were somehow involved in resistance to rituximab therapy, and we proposed that C-terminal deletion mutations of CD20 might be related to relapse/resistance after rituximab therapy.1 Many of these C-terminal truncated CD20 molecules were not recognized by the L26 monoclonal antibody used routinely in most clinical laboratories. Therefore, expression of CD20 seemed to have been completely lost for these lymphomas. However, an immunohistochemical study using a polyclonal antibody showed that some kind of C-terminal truncated CD20 was present in cytoplasm, so it was possible that the epitope of L26 was lost by gene mutations.1 L26 recognizes the cytoplasmic region of CD20 molecules, but no more detailed information about its epitope had been reported.2,3 In this study, we determine a recognition site of L26 by using a series of deletion mutants of CD20 molecules. In addition, to detect every one of the mutated CD20 molecules, we developed new antibodies that recognize the N-terminal region of CD20 molecules. We used these antibodies to identify cells that have CD20 molecules with abnormalities in the C-terminal cytoplasmic region. We characterized these mutated CD20 molecules using living primary lymphoma cells.

Materials and methods

Cells, viruses and DNA constructs
The coding region of the CD20 gene was amplified by reverse transcription PCR (RT-PCR) from RNA extracted from a Burkitt’s lymphoma cell line, Raji, and was cloned into a pDONAI retroviral vector (Takara, Ohtsu, Japan). A series of deletion mutants of CD20 in the C-terminal cytoplasmic region was constructed by inserting stop codons after nucleotides encoding E281, E263, E245, V228 and G210. Retroviruses carrying wild type and deletion mutants of CD20, together with mock construct, were produced with the transient retrovirus packaging cell line G3T-hi (Takara) according to the manufacturer’s protocol. Packaged retrovirus vectors were then used to infect a myeloma cell line, KMS12PE,4 with subsequent selection using 500 μg/ml G-418.

For the transfection of mutant CD20 gene, whole coding region of CD20 complementary DNA (cDNA) prepared by RT-PCR of total RNA isolated from the patient cells was cloned into first cassette of a bicistronic retrovirus vector carrying a green fluorescent protein (Takara, Ohtsu, Japan). A bicistronic expression of ZsGreen is facilitated by internal ribosomal entry site only when the presence of a myeloma cell line, KMS12PE,4 with subsequent selection using 500 μg/ml G-418.

Generation of monoclonal antibody secreting hybridomas
A synthetic peptide corresponding to residues 23–36 of human CD20 with one additional cysteine at the N-terminus (CMQSGPKPLFRMSS) was synthesized. The peptide was coupled with keyhole limpet hemocyanin. BALB/c mice were primed with a subcutaneous injection of the keyhole limpet hemocyanin-conjugated synthetic peptide emulsified in Freund’s complete adjuvant. Mice were boosted four times at two-week intervals with the same antigen. Mice that developed antibodies as measured by enzyme-linked immunosorbent assay with the immunizing peptide were boosted intravenously with the same peptide 4 days before splenocytes were harvested and fused to mouse myeloma cells. Hybridization and cloning were performed according to standard procedures.5

CD20 gene sequencing
Pleural effusion mononuclear cells were obtained by density gradient centrifugation using Ficoll-Hypaque 1.077 (Sigma,
CD20 mutations of rituximab-resistant lymphoma
Y Mishima et al

St Louis, MO, USA). The isolated mononuclear cells then underwent negative immunomagnetic selection using a B Cell Isolation Kit II (Miltenyi Biotec, Bergisch Gladbach, Germany) for purifying B-lineage cells. Total RNA was prepared using TRIzol reagent according to the instructions of the manufacturer (Invitrogen, Carlsbad, CA, USA) and 1 μg was subjected to reverse transcription under MMLV reverse transcriptase (Takara). To prepare cDNA-containing whole coding region of CD20, PCR amplification was performed from 2 μl of cDNA using primers outside of the start and the stop codon: hCD20-5'-TCCTGCTCTATGTCGAGCTA-3' and hCD20-3'-REV (5'-GCAGCTAGCATCCAAATCAG-3'). To determine the sequence of the CD20, we performed cycle sequencing on a 3130 DNA analyzer (Applied Biosystems, Foster City, CA, USA), directly from PCR-purified products, in both directions using a BigDye Terminator Cycle Sequencing Kit v3.1 (Applied Biosystems).

**Immunocytochemistry**

Cells were stained by rituximab and L26 antibody (DAKO, Carpentry, CA, USA) sequentially. Briefly, the cells were labeled by incubating in 10 μg/ml of rituximab conjugated with Alexa Fluor 647 (Invitrogen) according to previously described procedure and washed twice with phosphate-buffered saline. Rituximab-labeled cells were swelled by treatment with 75 mM KCl and then were made to adhere onto collagen I-coated cover glass by brief centrifugation. After fixing and permeabilization, the specimens were exposed to L26 antibody. Subsequently, the specimens were washed and were incubated in Alexa488-conjugated goat anti-mouse IgG. Nuclear staining was performed using 5 μg/ml of 4′,6-diamidino-2-phenylindole. The preparations were screened for fluorescence with a confocal microscope (FV1000, OLYMPUS, Tokyo, Japan) using excitation wavelengths of 405, 488 and 633 nm to detect emission by nuclear staining (4′,6-diamidino-2-phenylindole), rituximab or L26 staining, respectively.

**Immunohistochemistry**

The tissues had been routinely fixed in 10% neutral formalin and embedded in paraffin. L26 antibody and monoclonal antibodies raised against the N-terminal cytoplasmic region of CD20 were used. The sections were deparaffinized and rehydrated in graded alcohol. For heat-induced epitope retrieval, the sections were subjected to Target Retrieval Solution, pH 9 (DAKO) at 97°C for 40 min. The sections then were brought to an automated stainer (DAKO) by following the vendor’s protocol. EnVision Plus (DAKO) and peroxidase detection methods were used.

**Rituximab-binding analysis**

Rituximab-binding analysis was performed according to our previously developed imaging-based procedure, with some modifications. Briefly, approximately ten thousands of purified living lymphoma cells using a Dead cell removal kit (Miltenyi Biotec) were incubated with 10 μg/ml of anti-CD19 mAb labeled with Alexa Fluor 488 (Invitrogen) and rituximab labeled with Alexa Fluor 647 (Invitrogen) for 30 min at 4°C. The cells were washed with phosphate-buffered saline two times and were then suspended in 4 μl of RPMI1640 medium supplemented with 10% fetal bovine serum and 5 μg/ml of Hoechst 33342. The cell suspension was pipetted into a well made of silicon, 2.5 mm in diameter and 2 mm in depth, on a piece of cover glass. Images were collected by means of an OLYMPUS PlanApo × 60 oil objective in an OLYMPUS FV-1000 confocal microscope (OLYMPUS). The fluorophore was excited by laser at 405, 488 or 633 nm. The cells were optically sectioned along the z-axis, and the images were collected at 640 × 640 pixel resolution in a sequential mode to minimize the crossover between channels. The step size in the z-axis was 0.5 μm. For three-dimensional reconstruction, two-dimensional confocal stacks were saved in an Olympus.oib format and three-dimensional images were generated using Fluoview software (OLYMPUS).

**Cell sorting and genetic analysis**

The cryopreserved B-lineage cells of the pleural effusion at relapse were further sorted into two fractions of the cells with high affinity to rituximab (R-high) and those of low (R-low) by using flow cytometry (FACSvantage, Becton Dickinson, Franklin Lakes, NJ, USA). The cells were labeled with rituximab conjugated with AlexaFluor488 (Invitrogen) and anti-CD19-PE (Becton Dickinson), then resuspended in phosphate-buffered saline containing 2 μg/ml of 7-AAD (Sigma) to exclude dead cells. The sorting gate used for ‘R-high’ was rituximabbright/CD19+/7-AAD–, and for ‘R-low’ was rituximablow/CD19+/7-AAD–. The sorted cells were immediately used for extraction of both genomic DNA and total RNA using QIAamp DNA micro kit and RNeasy micro kit, respectively, (QIAGEN, Hilden, Germany). For amplifying the DNA-containing exon 8 of CD20 from genomic DNA, PCR was carried out using the forward primer (5′-TTCTGTITTIT2GAAACATAGTCTCCCTGATTCA-3′) and the reverse primer (5′-CAGAAGACAGAAATCAC5TAGAAGCG-3′). RT-PCR to amplify the CD20 cDNA were performed according to the method described above. The PCR and RT-PCR products were used to determine the CD20 gene sequence by direct sequencing method. In addition, 1 μl of RT-PCR products were cloned into a TA-cloning vector (pCR2.1, Invitrogen) and CD20 DNA sequences of 16 clones of each RT-PCR product were cloned into a TA-cloning vector (pCR2.1, Invitrogen) and sequenced by direct sequencing method. In addition, 1 μl of RT-PCR products were cloned into a TA-cloning vector (pCR2.1, Invitrogen) and 16 clones of each RT-PCR product were determined for estimating the ratio of different sequences.

**Results**

To confirm the epitope of L26, we made a series of constructs of the CD20 molecules with deletion mutations in the C-terminal cytoplasmic domain and introduced them into retrovirus vectors (Figure 1a). KMS12PE cells, in which expression of CD20 is not detected immunohistologically, were then transformed, and we established six kinds of sub-lines with the various C-terminal deletion mutations of CD20. A semi-quantitative RT-PCR analysis using a primer set designed to amplify the CD20 N-terminal region indicated that no major difference was found in CD20 messenger RNA (mRNA) expression of the six cell lines (Figure 1b). We carried out immunocytochemical analysis using L26 and fluorescence-labeled rituximab against these six CD20-expressing transfectants, along with a mock transfectant and Raji cells as negative and positive controls, respectively. The cells stained by L26 antibody were only those expressing wild type (amino acid 1–297) and DM1 mutant (amino acid 1–281). On the other hand, rituximab could bind to shorter CD20 molecules, such as DM2, DM3 or DM4, as well as to the CD20 molecules recognized by L26 (Figure 1c). These results indicate that L26 antibody recognizes the C-terminal cytoplasmic region of CD20 molecules and that its epitope is present in the amino-acid sequence of 264–281. The data suggest that immunohistochemistry using L26 antibody will exhibit a false negative if a deletion or a frame shift occurs upstream of this epitope. In addition, the shortest deletion mutant DM5 that lacked the C-terminal cytoplasmic region was detected by
CD20 mutations of rituximab-resistant lymphoma
Y Mishima et al

Figure 1. Search for epitopic site of L26 antibody and analysis of the extracellular exposure of CD20 molecules having C-terminal deletion mutation. (a) To explore the binding site of the L26 antibody, we constructed various lengths of the CD20 deletion mutant at their C-terminal cytoplasmic domain, TM: transmembrane domain. (b) KMS12PE cells retrovirally transduced with C-terminal truncated CD20 showed approximately similar levels of mRNA expression. (c) Immunocytochemical studies suggested that L26 recognizes amino-acid sequence between 264 and 281. An objective lens of × 60 was used with a × 10 digital zoom, bar: 5 μm. DAPI, 4’-6-diamidino-2-phenylindole; DIC, differential interference contrast; G3PDH, glyceraldehyde-3-phosphate dehydrogenase; WT, wild type.

| CD20 | DIC | DAPI | Rituximab | L26 | Merge |
|------|-----|------|-----------|-----|-------|
| KMS12PE/mock | CD20 (WT) | (aa 1-297) | | | |
| CD20 (DM1) | (aa 1-281) | | | | |
| CD20 (DM2) | (aa 1-283) | | | | |
| CD20 (DM3) | (aa 1-245) | | | | |
| CD20 (DM4) | (aa 1-228) | | | | |
| CD20 (DM5) | (aa 1-210) | | | | |
| Raji | | | | | |

Neither L26 antibody nor rituximab. Possible reasons might include the low membrane localization of DM5 mutant and/or low stability of the post-translational product. To clarify this, we carried out western blot analysis using total cell lysate of the series of deletion mutants that were tagged by FLAG peptide at the N-terminal region of CD20 constructs. We found that the cellular protein level of the DM5 deletion mutant of CD20 was remarkably lower than that of others, suggesting that low post-translational stability may be the reason for the low antigenicity of DM5 mutant (data not shown).

To detect CD20 in the clinical specimens that acquired rituximab resistance mutations, we developed novel anti-CD20 antibodies and screened them in paraffin sections. We isolated an antibody specific for the CD20 N-terminus and named it CD20N. Using this antibody, we carried out immunohistochemistry conducted on the CD20-negative cases by L26 antibody-based analysis and found several cases with mutations in the C-terminal cytoplasmic region. Among them, a cell specimen, a part of which had been cryopreserved as living cells, was included. This was pleural effusion from a patient with relapsed diffuse large cell B-cell lymphoma after complete remission following rituximab containing chemotherapy (rituximab, cyclophosphamide, adriamycin, vincristine and prednisone). This patient did not respond to further treatment with salvage therapies containing rituximab. The cryopreserved B lymphocytes of the pleural effusion at relapse were sorted into two fractions of cells of high affinity to rituximab (Figure 3b). Furthermore, flow cytometry analysis revealed that the fluorescent intensity of fluoro-labeled monoclonal antibody of CD20 decreased to less than one-tenth in about half of the B-cell population (Figure 3c). These results indicate that the C-terminal mutation of the CD20 gene in this case caused abnormality of extracellular-antigen presentation, even though the protein expression and the cell membrane localization seemed to be normal.

To reveal the genetic mechanisms of the reduced antigenicity to rituximab, we conducted gene-sequencing analysis about both population of cells that differ in affinity to rituximab. The cryopreserved B lymphocytes of the pleural effusion at relapse were sorted into two fractions of cells of high affinity to rituximab (R-high) and those of low (R-low) by using flow cytometry (Figure 4a). Then genomic DNA and total RNA from each fraction were extracted. The results of DNA sequencing of exon 8 of CD20 in which the mutation was found demonstrated that, surprisingly, both cell populations had both normal and the monobasic deletion mutant CD20 genes. To determine the proportion of the genes, the PCR-amplified DNA fragments were inserted into a TA-cloning vector and 16 clones from both ‘R-high’ and ‘R-low’ fractions were determined the sequence of CD20. As a result, the ratio of mutant DNA accounted for approximately half of genomic DNA of both ‘R-high’ (7 out of 16) and ‘R-low’ (9 out of 16). On the other hand, the results of sequence analysis about the cDNA revealed that the ratio of mutant mRNA in ‘R-low’ was remarkably increased (14 out of 16), whereas that of ‘R-high’ was as the same of the results of genomic DNA (8 out of 16; Figure 4b). We also carried out a sequence analysis about genomic DNA from a slice of paraffin-embedded tissue of lymph node at the first diagnosis of this patient, and found that approximately half of the genomic DNA
included the mutant CD20 gene same as the cells at relapse (8 out of 16; Figure 4c). These results indicated that this patient had already carried the mutation in CD20 gene, as onset of primary lymphoma, and that a transcriptional imbalance of wild-type CD20 and mutated CD20 have occurred by undetermined mechanisms in some cell populations.
As CD20 is thought to be present as a tetramer in cells, mutated CD20 may affect also wild-type peptide in the same cell. To verify this possibility, we introduced the CD20 gene carrying the same mutation as this patient to CD20/κ cell line, KMS12PE and CD20⁺ Daudi using a retrovirus vector, then selected the cells expressing the exogeneous CD20 by a green fluorescent protein reporter promoted by an internal ribosome entry site (Figure 5a). As the result of evaluating the binding affinity to rituximab by flow cytometry, the exogeneous mutated CD20 exhibited remarkably attenuated antigenicity to rituximab as compared with the wild-type CD20 (Figure 5b). Next, we transformed Daudi cells with the mutant CD20 to examine the effect on expression of wild-type CD20 molecules.

In consideration of turnover of intrinsic CD20, we evaluated binding of rituximab to the transfectants 7 days after virus infection. As shown in Figure 5c, the expression of this mutated CD20 was found to have hardly affected the affinity for rituximab. These results suggested that at least the mutation found in this patient did not exert a dominant negative effect against normal CD20 molecules.

Discussion

Previously, we reported that mutations in the CD20 gene were found with some frequency in patients treated with rituximab.
These cases often have a diagnosis of CD20 negative by immunostaining, based on the commonly used L26 antibody, and are difficult to distinguish from the cases in which protein expression of CD20 is extremely low. So the mutation in the CD20 gene has been less noticed with regard to resistance to rituximab. In the present study, we roughly identified the epitope of L26, and it became clear that all of the C-terminal-mutated CD20 that we had found earlier lost the epitope for L26, because the epitope was located near the C-terminal of CD20 molecule. To detect CD20 with these mutations comprehensively, we developed monoclonal antibodies that recognize a part of the amino-acid sequence of the N-terminal cytoplasmic region of CD20. One of these antibodies, CD20N, recognized CD20 proteins, including those having a mutation in the paraffin-embedded, formalin-fixed specimen. In this study, we showed that it could be applied to the primary screening of the lymphoma cells that express mutated CD20 by selecting L26-negative and CD20N-positive cells.

To date, there are not many reports that the mutation of the CD20 gene contributes to resistance to rituximab. A part of the reason for this may be that L26 cannot detect most of mutated CD20. In addition, Johnson et al. carried out a sequencing screening of exon 5 of the CD20 gene encompassing the epitope of rituximab. They detected CD20 mutations involving the rituximab epitope in only 1/264 (0.4%) and 1/15 (6%) of the biopsies taken at diagnosis and relapse, respectively. Similarly, in our previous screening, no mutation was found in the region of exon 5, whereas four cases with mutation (out of 50) were found in the C-terminal cytoplasm region of CD20. In the CD20 gene, a genetic mutation could be more likely to occur in the C-terminal region compared with around the region of rituximab epitope by uncertain mechanism(s).

Figure 5  The effect of mutant CD20 on wild-type CD20 with respect to rituximab binding. (a) The schematic diagram of retrovirus vectors used for transduction of wild-type and mutant CD20. (b) The transfectants were labeled with PE-conjugated, rituximab and analyzed by flow cytometry at seven days after viral infection. The contour plots of KMS12PE cells transfected with wild-type (upper panel) or mutated CD20 (lower panel) are shown. (c) Daudi cells were transfected with mutated CD20 and analyzed the rituximab-binding. The mutant CD20 introduced exogenously hardly affected the binding of rituximab to Daudi cells. IRES, internal ribosome entry site; LTR, long terminal repeat; wt, wild type; mt, mutant.
By using live cryopreserved cells, derived from a newly identified case with the mutation in the CD20 gene, we successfully analyzed in detail the phenotype of lymphoma cells having mutated CD20. In this case, a frame shift mutation occurred because of one base nucleotide deletion, resulting in the translation of peptide of another reading frame of 41 amino acids after the amino acid position 250 with a slight early termination. Immunohistochromatic analysis using CD20N antibody revealed that the CD20 molecules with C-terminal mutations were indeed expressed in the lymphoma cells, and located at the cell membrane. However, the living cell binding evaluation showed that rituximab could scarcely bind to these cells. These results suggest that the C-terminal region of CD20 undertakes a critical role in presentation of the large loop in which the rituximab-binding site locates.

As a result of genetic analysis for lymphoma cells, it was suggested that this patient had a mutation in the CD20 gene as onset of primary lymphoma. Because normal and mutated CD20 gene were almost the same copy numbers and the most of cells in the lymph follicle were stained in L26 at the first diagnosis, it can be considered that the lymphoma cells of this patient had equal number of normal and mutated CD20 alleles rather than the mixture of the cells having only normal CD20 allele(s) or only mutant allele(s). And at the relapse, two cell populations of the different affinity for rituximab has arose (‘R-high’ and ‘R-low’), and both had a genome of the same mutation status, however, the expression of the mutated mRNA has been predominant only in ‘R-low’. As a result of semi-quantitative RT-PCR analysis revealed that whole CD20 mRNA expression of ‘R-low’ slightly decreased as compared with that of ‘R-high’ (data not shown), the imbalanced mRNA expression in ‘R-low’ may be due to the suppression of CD20 mRNA expression from the wild-type allele at the transcription level.

To summarize these data, the primary lymphoma cells of this patient expressed both wild-type and mutated CD20 equally. As CD20 in this case was found to have little effect on the antigenicity of wild-type CD20 molecules, these cells were still susceptible to rituximab plus CHOP and the patient has obtained complete remission. However, at the relapse, cells that predominantly expressed the mutant CD20 emerged. This mutant molecule expressed and localized at the plasma membrane, however, the large loop could not be oriented appropriately. So it was considered that rituximab-containing salvage treatments have failed perhaps because affinity for rituximab was not enough.

It was noteworthy that the antibody that recognizes N-terminal region of CD20 has capability to detect the mutated CD20 before start of the salvage therapy. This indicated the possibility that we can predict the existence of lymphoma cells resistant to rituximab before start of therapy. In addition, this information may provide important criterion to judge whether it should switch to the treatment such as using second-generation CD20 antibody that is effective against fewer CD20-expressing cells, or using antibody for the different target molecule such as CD22.

The resistance for a molecular target drug acquired by a mutation in the gene of the target molecule is commonly considered to be irreversible. We propose here that detecting a mutation in the gene by screening using antibodies of two kinds of epitope is useful in detection of irreversible resistant mutation for molecular targeted drug including rituximab.

Conflicts of interest

The authors declare no conflict of interest.

Acknowledgements

We thank Ms Sayuri Minowa, Ms Harumi Shibata and Ms Mariko Mikuniya for their assistance in specimen preparation. We also thank Dr Dovie Wylie of On-Site English, Inc. (Palo Alto, CA, USA) for English editing assistance.

References

1. Terui Y, Mishima Y, Sugimura N, Kojima K, Sakurai T, Kuniyoshi R et al. Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin’s lymphoma. Clin Cancer Res 2009; 15: 2523–2530.
2. Mason DY, Cormans-Bitter WM, Cordell JL, Verhoeven MA, van Dongen J. Antibody L26 recognizes an intracellular epitope on the B-cell-associated CD20 antigen. Am J Pathol 1990; 136: 1215–1222.
3. Norton AJ, Isaacson PG. Monoclonal antibody L26: an antibody that is reactive with normal and neoplastic B lymphocytes in routinely fixed and paraffin wax embedded tissues. J Clin Pathol 1987; 40: 1405–1412.
4. Hata H, Matsuzaki H, Matsuno F, Sonoki T, Takezono S, Kuribayashi N et al. Establishment of a monoclonal antibody to plasma cells: a comparison with CD38 and PCA-1. Clin Exp Immunol 1994; 96: 370–375.
5. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495–497.
6. Mishima Y, Sugimura N, Matsumoto-Mishima Y, Terui Y, Takeuchi K, Asai S et al. An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy. Clin Cancer Res 2009; 15: 3624–3632.
7. Polyak MJ, Li H, Shariat N, Deans JP. CD20 homo-oligomers physically associate with the B cell antigen receptor. Dissociation upon receptor engagement and recruitment of phospho-proteins and calmodulin-binding proteins. J Biol Chem 2008; 283: 18545–18552.
8. Johnson NA, Leach S, Woolcock B, deLeeuw RJ, Bashashati A, Sehn LH et al. CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure. Haematologica 2009; 94: 423–427.
9. Pawlułowczyk AW, Beurkens FJ, Beum PV, Lindorfer MA, van de Winkel JG, Parren PW et al. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009; 183: 749–758.
10. Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A et al. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008; 111: 5486–5495.
11. Patz M, Isaeva P, Forcob N, Muller B, Frenzel LP, Wendtner CM et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 2011; 152: 295–306.
12. Mossner E, Brunker P, Moser S, Puntener U, Schmidt C, Herter S et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010; 115: 4393–4402.
13. Dijoseph JF, Dougher MM, Armellino DC, Evans DY, Damle NK. Therapeutic potential of CD22-specific antibody-targeted chemo-therapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia. Leukemia 2007; 21: 2240–2245.
14. Dijoseph JF, Goad ME, Dougher MM, Boghaert ER, Kunz A, Hamann PR et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamycin, against systemically disseminated B-cell lymphoma. Clin Cancer Res 2006; 12: 8620–8629.
15. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF et al. Acquired resistance of lung adenocarcinomas to gefitinib or
erlotinib is associated with a second mutation in the EGFR kinase domain. *PLoS Med* 2005; 2: e73.

16 Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. *Clin Cancer Res* 2008; 14: 2895–2899.

17 Shah NP, Sawyers CL. Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. *Oncogene* 2003; 22: 7389–7395.

18 Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. *Cancer Cell* 2002; 2: 117–125.

19 Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S et al. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. *Cancer Cell* 2006; 10: 25–38.

This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/